ALPS Advisors’s Compass Therapeutics CMPX Stock Holding History

ALPS Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$246K	Buy	236,892 +54,115	+30%	+$112K	﹤0.01%	1096
2026 Q2	$400K	Buy	182,777 +36,170	+25%	+$107K	﹤0.01%	1048
2026 Q1	$776K	Buy	146,607 +567	+0.4%	+$3.27K	﹤0.01%	622
2025 Q4	$784K	Buy	146,040 +63,033	+76%	+$291K	﹤0.01%	629
2025 Q3	$291K	Buy	83,007 +8,410	+11%	+$26.6K	﹤0.01%	994
2025 Q2	$194K	Buy	+74,597	New	+$154K	﹤0.01%	1008
2023 Q4	–	Sell	-94,115	Closed	-$185K	–	973
2023 Q3	$185K	Buy	94,115 +1,127	+1%	+$2.79K	﹤0.01%	958
2023 Q2	$296K	Buy	+92,988	New	+$292K	﹤0.01%	884

Other funds holding CMPX

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Simplicity Wealth Summit, New Jersey $3.43B AUM 16.22% 1-Year Est. Return

Independent Financial Group San Diego, California $5.51B AUM 33.51% 1-Year Est. Return

McAdam LLC Philadelphia, Pennsylvania $2.66B AUM 14.82% 1-Year Est. Return

ALPS Advisors's CMPX Position: Q3 2026 in Review

ALPS Advisors increased its Compass Therapeutics (CMPX) stake by 30% in Q3 2026, buying an estimated $112K and bringing the position to 236,892 shares worth $246K. The position accounts for ﹤0.01% of the portfolio, ranked #1096.

ALPS Advisors first reported a position in CMPX in Q2 2023 and has held it in 8 quarters since. The position peaked at $784K in Q4 2025. 33 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

ALPS Advisors held 236,892 shares of Compass Therapeutics worth $246K as of Q3 2026.
ALPS Advisors bought 54,115 Compass Therapeutics shares in Q3 2026, an estimated $112K.
Compass Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q3 2026, its #1096 holding.
ALPS Advisors first reported a position in Compass Therapeutics in Q2 2023 and has held it in 8 quarters since.
ALPS Advisors's Compass Therapeutics position peaked at $784K in Q4 2025.
33 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.